Joachim Fruebis

Joachim Fruebis is a seasoned professional in the pharmaceutical and biotechnology sectors, currently serving as Corporate Vice President and head of Cell Therapy R&D at Novo Nordisk since July 2023. With a robust background in research and development, Joachim held several leadership roles including Chief Development Officer at BlueRock Therapeutics and Senior Vice President of Development at Bioverativ, a Sanofi company. Previous positions include Vice President of Clinical Development at Bayer, where responsibilities included late-stage development and commercialization of multiple therapeutic programs, and Vice President roles at Pfizer, focused on external R&D in rare diseases and hematology. Joachim's career also features significant contributions at Boehringer Ingelheim Pharmaceuticals, ZymoGenetics, Genset, and the University of California at San Diego. Joachim holds a Ph.D. in Biology from RPTU Kaiserslautern-Landau and an Abitur from Leininger Gymnasium.